Johnson & Johnson Stock: After Last Year’s 50% Surge, Can the Momentum Continue?

Johnson & Johnson (JNJ) saw a significant surge in 2025 sales and anticipates hitting $100 billion in 2026, driven by a strategic pivot towards high-growth oncology and immunology segments and the exploration of a $20+ billion sale of DePuy Synthes. Despite strong growth in key products like TREMFYA and CARVYKTI, and institutional confidence through co-funding agreements, Wall Street’s mean price target suggests a potential near-term downside, although TIKR’s valuation model projects substantial long-term returns. The stock’s future hinges on successful product launches like ICOTYDE and management of ongoing talc litigation.